AzurRx BioPharma Announces Reverse Merger With First Wave Bio

Benzinga

2021-09-13

AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments.
First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).
In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.
In January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients.
Following the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.
Last week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.
Also Read: Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?
Price Action: AZRX shares are trading at $5.16 during the premarket session on the last check Monday.

See more from Benzinga

Click here for options trades from Benzinga
RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa
Why Are Leap Therapeutics Shares Trading Higher On Monday?

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2167873975"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2167873975\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2167873975?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZRBBOa1tMJViMFVc8fXmEg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/0FNyfQ5yut_c43zYJ0mE8A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3","is_english":true,"pubTime":"2021-09-13 21:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2167873975","market":"us","top_or_hot":-1,"title":"AzurRx BioPharma Announces Reverse Merger With First Wave Bio","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/6BKrdrb.0YA.QwatkjOnfg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>AzurRx BioPharma Inc</strong> (NASDAQ: AZRX) has agreed to acquire <strong>First Wave Bio Inc</strong> in a stock and cash transaction valued at $229 million, including milestone payments. </li>\n<li>First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).</li>\n<li>In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.</li>\n<li>In January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients. </li>\n<li>Following the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.</li>\n<li>Last week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. </li>\n<li><strong><em>Also Read:</em></strong><em> </em><em>Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?</em></li>\n<li><strong>Price Action:</strong> AZRX shares are trading at $5.16 during the premarket session on the last check Monday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa</li>\n<li>Why Are Leap Therapeutics Shares Trading Higher On Monday?</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AzurRx BioPharma Announces Reverse Merger With First Wave Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAzurRx BioPharma Announces Reverse Merger With First Wave Bio\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-09-13 21:19</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/6BKrdrb.0YA.QwatkjOnfg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>AzurRx BioPharma Inc</strong> (NASDAQ: AZRX) has agreed to acquire <strong>First Wave Bio Inc</strong> in a stock and cash transaction valued at $229 million, including milestone payments. </li>\n<li>First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).</li>\n<li>In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.</li>\n<li>In January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients. </li>\n<li>Following the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.</li>\n<li>Last week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. </li>\n<li><strong><em>Also Read:</em></strong><em> </em><em>Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?</em></li>\n<li><strong>Price Action:</strong> AZRX shares are trading at $5.16 during the premarket session on the last check Monday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa</li>\n<li>Why Are Leap Therapeutics Shares Trading Higher On Monday?</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/azurrx-biopharma-announces-reverse-merger-131954264.html\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/azurrx-biopharma-announces-reverse-merger-131954264.html","article_id":"2167873975","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZRBBOa1tMJViMFVc8fXmEg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/0FNyfQ5yut_c43zYJ0mE8A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5320086803c22ca695d32783aaa0b7d3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2167873975","pubTimestamp":1631539194,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash tra","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"AzurRx BioPharma宣布与First Wave Bio反向合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZRX":0.9},"content_text":"AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. \nFirst Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).\nIn conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by September 23.\nIn January, AzurRx in-licensed from First Wave Bio the exclusive global rights to develop two niclosamide therapeutic indications for COVID-19-related GI infections and immune checkpoint inhibitor-associated colitis and diarrhea (ICI-AC) in advanced-stage cancer patients. \nFollowing the acquisition of First Wave Bio, AzurRx's internal development pipeline will include three new clinical IBD indications.\nLast week, AzurRx BioPharma announced a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. \nAlso Read: Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?\nPrice Action: AZRX shares are trading at $5.16 during the premarket session on the last check Monday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nRedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa\nWhy Are Leap Therapeutics Shares Trading Higher On Monday?\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}